Reign Health & Wellness
The terms "health" and "wellness" are often used interchangeably, but they have distinct meanings. Health refers to a state of physical well-being where the body is free from disease or illness. On the other hand, wellness is an active and ongoing process of pursuing balance and harmony across multiple areas of life.
Exploring the Depths of Wellness, Beyond Physical Health
Wellness encompasses a broader range of factors beyond physical health, including social, spiritual, emotional, intellectual, environmental, and occupational well-being. Achieving wellness requires conscious choices and actions that promote health and fulfillment in each area.
Taking control of our health and wellness is the key to reigning over our lives with strength and vitality."
~ Reign Health & Wellness
Our Unique Approach To Medical Weight Loss:
We offer a unique and innovative approach to weight management through our specialized compounded peptide therapy. Our primary aim is to optimize health and wellness. We do this by providing personalized compounds like Semaglutide and Tirzepatide, in conjunction with oral medications and vitamin injections, colloquially referred to as 'Skinny Shots.
Semaglutide and Tirzepatide have shown efficacy in weight loss and weight management. Our compounded formulations are carefully crafted to optimize their benefits and deliver personalized solutions. Whether used in combination with other therapies or as standalone options, our compounded treatments are designed to provide cutting-edge results tailored to your specific needs.
Is It Right For You?
Schedule an initial consultation to determine if you qualify for our program. We currently serve clients in Missouri and Kansas and are actively working towards expanding our services to other states.
Comprehensive blood tests play a vital role in understanding your overall health and wellness. We utilize these tests to gain valuable insights into your body and tailor our approach accordingly.
Our certified providers conduct thorough consultations where they review your medical history, discuss your weight loss goals, and assess your eligibility for our Medical Weight Loss Program. This one-on-one session includes a personalized consultation and an in-depth analysis of your blood panels to inform our strategy. If any deficiencies are detected, we address them accordingly and determine if you are a suitable candidate for our customized program.
We firmly believe that personalized weight loss plans are key to long-term success. That's why we create tailored plans that specifically address your unique needs and goals. Our primary aim is to help you achieve your desired weight and sustain it over time.
Throughout your program, our expert team provides ongoing support and guidance. We are dedicated to providing you with education, advice, and encouragement every step of the way. For your convenience, we offer easy and secure HIPAA-compliant communication between appointments, ensuring a seamless experience.
According to Wilding et al. (2021), a study published in the New England Journal of Medicine showed that once-weekly injections of semaglutide resulted in greater weight loss than placebo injections among adults with overweight or obesity. The study found that after 68 weeks, patients who received semaglutide lost significantly more weight than those who received a placebo, and a greater proportion of patients in the semaglutide group achieved weight loss of 5% or more. Wilding suggests that these findings indicate that semaglutide could be an effective option for the treatment of obesity.
Wilding et al. (2021) found that in the study on Semaglutide, "once-weekly subcutaneous injection of semaglutide at a dose of 2.4 mg resulted in significantly greater weight loss than placebo over 68 weeks in adults with overweight or obesity." The study also showed improvements in cardiometabolic risk factors and quality of life. Additionally, the authors noted that "the proportion of participants with adverse events leading to withdrawal was low and similar in the two groups."
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., & STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183